Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06014502 |
TitleStudy to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2023-08-28 |
地点
Louisiana, United States
Texas, United States |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
IMGS-001 |
标签
MSI-H/ MMRd
|
| NCT ID NCT06013111 |
TitleAn Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors | 阶段
第 1 阶段
|
Date Added 2023-08-28 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06010901 |
TitleA Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. | 阶段
第 1 阶段
|
Date Added 2023-08-25 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Anlotinib hydrochloride capsules, Penpulimab Injection, TQB2618 injection |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06011772 |
TitleA Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | 阶段
早期阶段 1
|
Date Added 2023-08-25 |
地点
New York, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
暂停
|
药物
fluorouracil, Irinotecan, Leucovorin, oxaliplatin |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06008119 |
TitleEfficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | 阶段
第三阶段
|
Date Added 2023-08-23 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab, Tunlametinib plus Vemurafenib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06006923 |
TitleRegorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | 阶段
第二阶段
|
Date Added 2023-08-23 |
地点
California, United States
Florida, United States Illinois, United States Pennsylvania, United States Washington, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Pembrolizumab, Regorafenib, Keytruda, Stivarga |
标签
MSI-H/ MMRd
|
| NCT ID NCT05999812 |
TitleClinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer | 阶段
第二阶段
|
Date Added 2023-08-21 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
all trans Retinoic Acid, Atezolizumab, Bevacizumab |
标签
MSS/ MMRp
|
| NCT ID NCT05990543 |
TitleCombination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2023-08-14 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Nelmastobart and Capecitabine |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05976906 |
TitleUniversal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2023-08-04 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05973487 |
TitleA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | 阶段
第 1 阶段
|
Date Added 2023-08-03 |
地点
Arizona, United States
California, United States Connecticut, United States Florida, United States Illinois, United States Kentucky, United States Michigan, United States Minnesota, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
